Adtran to showcase industry-leading open optical networking for the AI era at OFC 2026
12.3.2026 14:00:00 CET | Business Wire | Press Release
Adtran today announced that it will showcase its latest optical innovations at OFC 2026, taking place from March 15 to 19 in Los Angeles. The company will outline how intelligent, secure and power‑efficient optical networks are shaping the next phase of AI infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311958018/en/
Adtran’s optical networking technology is helping build the foundation for the AI era.
At Adtran’s booth (1001), visitors can explore solutions spanning ultra‑low‑power intra‑data center connectivity, automated open optical transport, access evolution and AI‑enabled operations. Adtran experts will be available throughout the show for conversations and to guide visitors through hands-on demos, as well as leading a range of speaking sessions.
“As AI workloads scale, network operators and cloud providers need an optical foundation that can keep pace with unprecedented demand for capacity and efficiency,” said Christoph Glingener, CTO of Adtran. “Our technology is helping shape the AI era through open, power‑efficient optical architectures and intelligent automation that change the economics of scale. At OFC 2026, we’re demonstrating how operators can boost performance without increasing energy consumption or operational complexity.”
Technology highlights at OFC 2026
At OFC 2026, Adtran will present a broad portfolio of optical networking technologies designed to support scalable, energy‑efficient AI infrastructure across data center, transport and access networks.
- Ultra‑low‑power 800G connectivity
LiteWave800™ is a new class of 800Gbit/s pluggable optics for intra‑data center links. Operating at just 1pJ/bit, it sets a new efficiency benchmark for 800Gbit/s connectivity, dramatically reducing power consumption and thermal constraints in dense AI data center fabrics. - AI‑enabled operations
REAL AI will be demonstrated, showing how explainable, AI‑driven automation in network operations empowers operators to improve visibility, accelerate issue resolution and reduce operational complexity.
- Quantum‑safe networking for critical infrastructure
The Adtran FSP 3000 S‑Flex™ will be featured, highlighting quantum‑safe optical transport for mission‑critical networks, with ALM fiber assurance shown as a complementary layer for in‑service monitoring, network integrity and detection of physical network intrusion.
- Open optical transport and interoperability
Support for open, multi‑vendor optical networking will be highlighted through participation in OIF’s interoperability demo. This will feature Adtran’s 100Gbit/s, 400Gbit/s and 800Gbit/s ZR+ coherent pluggable optics, FSP 3000 open line system with C‑ and L‑band support and Mosaic Network Controller. Adtran’s pluggable optics also feature in related OIF plugfest activities.
- Access and edge evolution
Access and aggregation solutions, including 50G PON and innovative edge routing technology, will be shown supporting ultra-scalable, AI-ready services, with automated service‑activation platforms extending intelligence from the core through the door.
Sustainable research and data‑sovereign AI innovation
Beyond its commercial portfolio, Adtran will highlight its leadership in SUSTAINET‑Advance, a European collaborative research initiative focused on building sustainable, resilient and sovereign optical infrastructure.
Adtran is also contributing to demonstrations of the Optical Testbed Data Space (OTDS) in the OFC Demo Zone, showcasing how governed, cross‑domain data sharing can support AI development without exposing sensitive network information.
Together, these initiatives reflect Adtran’s commitment to responsible, standards‑driven innovation and to enabling AI‑ready networks while ensuring operational trust, data sovereignty and long‑term sustainability.
Visit Adtran at OFC 2026
Attendees are invited to visit Booth 1001 to explore Adtran’s technologies and engage with the company’s experts.
Multi‑vendor interoperability demonstrations can also be seen at the OIF booth (2017).
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260311958018/en/
Contacts
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Peter Schuman
+1 256 963 6305
investor.relations@adtran.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom